Home › Funds › ACUTA CAPITAL PARTNERS, LLC › MLTX
ACUTA CAPITAL PARTNERS, LLC position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 215,652 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$4.2M, representing 2.93% of its reported portfolio and ranking #12 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed MLTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's MLTX position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in MLTX in Q4 2025 at 59,280 shares (US$781K). The position peaked in Q2 2026 at 215,652 shares, worth US$4.2M. Across 3 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 215,652 shares valued at US$4.2M — an increase of 23,892 shares quarter over quarter.. Notable position changes include a 223% increase in Q1 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 59.28K | $781.31K | New |
| Q1 2026 | 191.76K | $3.57M | Add |
| Q2 2026 | 215.65K | $4.20M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 30 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held MLTX?
ACUTA CAPITAL PARTNERS, LLC has disclosed MLTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is ACUTA CAPITAL PARTNERS, LLC's current position in MLTX?
As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 215.65K shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $4.20M, representing 2.93% of its reported portfolio and ranking #12.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling MLTX?
In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in MLTX. The position peaked in Q2 2026 at 215.65K shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.